SCYNEXIS, Inc. (NASDAQ:SCYX) was founded in 1999, formerly known as SCYNEXIS Chemistry & Automation, Inc., changed its current name in June 2002, headquartered in Jersey City, New Jersey, USA, with 19 full-time employees, is a company A drug development company that develops and commercializes anti-infective drugs to solve unmet medical needs.
SCYNEXIS, Inc. (SCYX):
SCYNEXIS is developing its main product candidate SCY-078, as a new oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections.
SCYNEXIS has also developed various oral and intravenous formulations of SCY-078, which is currently in multiple phase I clinical research stages; it is also used as a hypotensive treatment for patients with invasive candidiasis and vulvovaginal candidiasis, and has completed phase II clinical trials. the study.
SCYNEXIS has conducted research cooperation with Merck Sharp & Dohme Corp. and R-Pharm, CJSC to develop and commercialize SCY-078.
